Veracyte(US:VCYT) Businesswire·2025-11-03 21:15Core Insights - Veracyte, Inc. has announced the publication of two studies demonstrating the capabilities of the Afirma GRID research tool in enhancing thyroid nodule evaluation and identifying molecular classifiers for cancer risk assessment [1][2][7] Study Findings - The first study focuses on developing mRNA-based classifiers to predict low-risk thyroid tumor features, conducted in collaboration with Memorial Healthcare System and Brigham and Women's Hospital [2][5] - The second study, independently conducted by researchers at Cleveland Clinic, investigates mRNA-based expression signatures to differentiate higher-risk tumors prior to surgery [2][4] Afirma GRID Overview - Afirma GRID is a research-use-only platform that utilizes whole transcriptome-derived data from over 21,000 expressed genes across more than 200,000 thyroid nodule samples [8] - The platform aims to provide enhanced prognostic information and guide treatment decisions for patients with thyroid nodules [7][9] Clinical Implications - The studies highlight the potential of gene expression profile signatures as preoperative predictive tools for high-risk features, which could improve recurrence risk stratification and inform surgical decisions [6][5] - The findings suggest that with further validation, these molecular signatures may lead to clinically useful prognostic markers for thyroid cancer [5][6]